Nivolumab,Doxorubicin,Vinblastine,dacarbazine 
BMS
['nivo', 'lymsm', 'nivolumab']
final analysis of nivahl in early-stage unfav chl. 7 pts with pr at eot all converted to cr without addn'l tx. 3-yr pfs was 100% in concomitant, 98% sequential. hypothyroidism seen (15% req'd lt4). pro data with clinically meaningful improvement in fatigue by 3 yrs. #ash22 #lymsm 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????